A Simple Online Calculator Detects Liver Cirrhosis Patients at High Risk for Clinical Complications

Researchers at CeMM, the Medical University of Vienna (MedUni Vienna), and the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD) joined efforts to use their expertise in machine learning and management of patients with cirrhosis to develop a non-invasive algorithm that can help clinicians to identify patients with cirrhosis at highest risk for severe complications. Cirrhosis develops in response to repeated injury to the liver, such as fatty liver disease or viral hepatitis. Initially, cirrhosis is mostly asymptomatic, thus, early identification of risk factors for severe complications represents an unmet clinical need.

There are two clinical stages of liver cirrhosis: compensated and decompensated. Patients with compensated liver cirrhosis have very few or even no symptoms. However, patients may progress decompensated cirrhosis, which occurs with severe complications such as internal (variceal) bleeding or by an accumulation of fluid in the abdomen (ascites) and may even lead to death. Unfortunately, the measurement of the risk of decompensation in patients with compensated cirrhosis currently requires an invasive procedure. i.e., the measurement of the hepatic venous pressure gradient (HVPG). An elevated HVPG ≥10 mmHg is associated with a higher probability of complications. Patients with an even higher HVPG of ≥16 mmHg are at imminent risk for hepatic decompensation.

In a study by first authors Jiri Reinis from Stefan Kubicek's group at CeMM and Oleksandr Petrenko from Thomas Reiberger's group at MedUni Vienna, CeMM, and LBI-RUD, machine learning models were trained on blood test parameters obtained from patients with compensated cirrhosis to detect elevated levels of portal vein pressure, thereby identifying those at risk for developing clinical complications. The study was now prominently published in the Journal of Hepatology.

Best clinical parameters for prediction

The key data sources used in the project were derived from the ongoing Vienna Cirrhosis Study, conducted at the Division of Gastroenterology and Hepatology of the MedUni Vienna at the Vienna General Hospital. For this study, HVPG measurements were performed in 163 compensated cirrhosis patients in whom blood samples were simultaneously obtained in order to determine a range of 124 biomarkers. Out of the entire set of clinical variables, three and five optimal parameters for the detection of high-risk patients were computationally determined. In the VICIS patient cohort, the model performed excellently for the identification of patients with HVPG values of ≥10 mmHg and ≥16 mmHg, respectively.

Validation of the dataset

To assess the diagnostic power of the non-invasive models to predict complications, the researchers tested their non-invasive machine learning model on a combined cohort of 1,232 patients with compensated cirrhosis from 8 European clinical centers. The novel approach was confirmed to be of excellent diagnostic value in the overall cohort and importantly is based on 3 or 5 widely available laboratory parameters only, is non-invasive, and does not require dedicated and expensive equipment. Project leader Thomas Reiberger explains "While an HVPG measurement is still required for reliable identification of patients with clinically significant or severe portal hypertension, the novel approach could be applied for prioritization for treatment to prevent decompensation or for selection of patients for clinical trials. Due to its simplicity, the proposed methodology could be eventually employed during routine check-ups at little additional cost."

Online calculator

Finally, the researchers developed an online calculator to allow clinicians to calculate the risk of decompensation for their patients with compensated cirrhosis, available at https://liver.at/vlsg/HVPG-Calculator/

Reiniš J, Petrenko O, Simbrunner B, Hofer BS, Schepis F, Scoppettuolo M, Saltini D, Indulti F, Guasconi T, Albillos A, Téllez L, Villanueva C, Brujats A, Garcia-Pagan JC, Perez-Campuzano V, Hernández-Gea V, Rautou PE, Moga L, Vanwolleghem T, Kwanten WJ, Francque S, Trebicka J, Gu W, Ferstl PG, Gluud LL, Bendtsen F, Møller S, Kubicek S, Mandorfer M, Reiberger T.
Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
J Hepatol. 2022 Sep 21:S0168-8278(22)03119-1. doi: 10.1016/j.jhep.2022.09.012

Most Popular Now

Mahana Therapeutics Signs Agreement with…

Mahana Therapeutics, a leading provider of prescription digital therapeutics, announced today that the company has entered into a multi-million-dollar distribution and marketing partnership with the Consumer Health division of Bayer...

ChatGPT can Outperform University Studen…

ChatGPT may match or even exceed the average grade of university students when answering assessment questions across a range of subjects including computer science, political studies, engineering, and psychology, reports...

NHS AI Diagnostic Funding: Five Things t…

Opinion Article by Guilherme Carvalho, Sales & Contracts Manager, Sectra. A new £21 million fund for AI was announced by the UK government in June, with the intention of providing NHS...

ChatGPT Shows Limited Ability to Recomme…

For many patients, the internet serves as a powerful tool for self-education on medical topics. With ChatGPT now at patients’ fingertips, researchers from Brigham and Women’s Hospital, a founding member...

Combining AI Models Improves Breast Canc…

Combining artificial intelligence (AI) systems for short- and long-term breast cancer risk results in an improved cancer risk assessment, according to a study published in Radiology, a journal of the...

AI Predictions for Colorectal Cancer: On…

Colorectal cancer (CRC) ranks second in leading causes of cancer-related deaths globally, according to the WHO. For the first time, researchers from Helmholtz Munich and the University of Technology Dresden...

Healthcare Chatbot: Expand Support with …

The Danish eHealth platform, sundhed.dk, has faced a substantial surge in requests from Danish citizens and has swiftly expanded its support and effectively adapt to the ongoing changes in queries due...

ChatGPT Shows 'Impressive' Acc…

A new study led by investigators from Mass General Brigham has found that ChatGPT was about 72 percent accurate in overall clinical decision making, from coming up with possible diagnoses...

WiFi SPARK's Healthcare Business Re…

Leading WiFi provider WiFi SPARK is rebranding its healthcare arm as SPARK Technology Services Limited. The new identity marks the completion of the integration of the former Hospedia bedside unit...

AI Performs Comparably to Human Readers …

Using a standardized assessment, researchers in the UK compared the performance of a commercially available artificial intelligence (AI) algorithm with human readers of screening mammograms. Results of their findings were...

ChatGPT is Debunking Myths on Social Med…

ChatGPT could help to increase vaccine uptake by debunking myths around jab safety, say the authors of a study published in the peer-reviewed journal Human Vaccines and Immunotherapeutics. The researchers asked...

Online AI-Based Test for Parkinson'…

An artificial intelligence (AI) tool developed by researchers at the University of Rochester can help people with Parkinson's disease remotely assess the severity of their symptoms within minutes. A study...